William Trenton Webb, who serves as American Group President at Surgery Partners, Inc. (NASDAQ: SGRY), completed two stock sales on March 5 and March 6, 2026, disposing of a combined 2,066 shares of common stock. Those transactions were executed at prices ranging from $13.86 to $13.93 and generated total proceeds of $28,653. According to the filing, the sales were executed to cover tax obligations associated with the vesting of restricted stock.
On the same March 5 filing, Webb was the recipient of a sizable restricted stock award consisting of 31,892 shares of Surgery Partners common stock. Those awards were recorded at a grant price of $14.11, giving the package a reported value of $449,996. The restricted shares are scheduled to vest on the first and second anniversaries of the grant date, per the disclosure. After accounting for the sales and the new grant, Webb directly owns 104,347 shares of company stock.
Surgery Partners shares are trading at $13.30, reflecting a 44% decline over the past year and sitting not far above the 52-week low of $12.25. InvestingPro analysis referenced in the company filing indicates a Fair Value of $14.60 for the stock, and the service is noted as offering seven additional exclusive tips for SGRY.
These insider transactions occur amid a flurry of corporate and market developments for Surgery Partners. The company announced the acquisition of Preferred Vascular Group, a provider focused on dialysis access procedures, with the deal reported at a market value of $6 billion. The transaction expands Surgery Partners' footprint by adding eight ambulatory surgical centers across Georgia and Ohio.
On the financial side, recent earnings and guidance prompted multiple brokerages to lower their price targets for Surgery Partners. RBC Capital, TD Cowen, Jefferies, and Benchmark each reduced targets, citing factors that included weaker-than-expected 2026 guidance, a shortfall in adjusted EBITDA-NCI versus expectations, and what analysts described as an earnings reset. Despite lowering targets, RBC Capital, TD Cowen, and Jefferies retained their positive ratings, and Benchmark retained a Buy rating.
Operational headwinds noted in company disclosures and analyst comments include a negative insurance mix shift and market-specific issues that affected performance at three surgical hospitals. Taken together, the insider transactions, strategic acquisition activity, and the series of analyst adjustments illustrate ongoing tactical and financial adjustments by Surgery Partners as it navigates recent performance challenges and a period of strategic expansion.
Key points
- William Trenton Webb sold 2,066 shares on March 5 and March 6, 2026, raising $28,653; sales were to cover taxes related to restricted stock vesting.
- Webb received 31,892 restricted shares on March 5 valued at $449,996 at a grant price of $14.11; these awards vest on the first and second anniversaries of the grant date, and he now directly owns 104,347 shares.
- Surgery Partners announced a $6 billion market-value acquisition of Preferred Vascular Group, adding eight ambulatory surgical centers in Georgia and Ohio, while several analysts lowered price targets after recent earnings and guidance.
Risks and uncertainties
- Analyst target reductions tied to weaker-than-expected 2026 guidance and adjusted EBITDA-NCI shortfalls create near-term valuation uncertainty for equity investors in the healthcare services sector.
- Operational pressures from a negative insurance mix shift and market-specific problems at three surgical hospitals could continue to weigh on margins and near-term cash flow for the company.
- Insider sales to cover tax obligations related to equity compensation can coincide with market volatility; investors should consider both equity dilution and timing when assessing executive transactions.
These developments reflect ongoing adjustments and strategic moves by Surgery Partners in the healthcare market.